Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
The selective estrogen-receptor modulator (SERM) tamoxifen became the first U.S. Food and Drug Administration (FDA)-approved agent for reducing breast cancer risk but did not gain wide acceptance for prevention, largely because it increased endometrial cancer and thromboembolic events. The FDA approved the SERM raloxifene for breast cancer risk reduction following its demonstrated effectiveness in preventing invasive breast cancer in the Study of Tamoxifen and Raloxifene (STAR). Raloxifene caused less toxicity (versus tamoxifen), including reduced thromboembolic events and endometrial cancer. In this report, we present an updated analysis with an 81-month median follow-up. STAR women were randomly assigned to receive either tamoxifen (20 mg/d) or raloxifene (60 mg/d) for 5 years. The risk ratio (RR; raloxifene:tamoxifen) for invasive breast cancer was 1.24 (95% confidence interval [CI], 1.05-1.47) and for noninvasive disease, 1.22 (95% CI, 0.95-1.59). Compared with initial results, the RRs widened for invasive and narrowed for noninvasive breast cancer. Toxicity RRs (raloxifene:tamoxifen) were 0.55 (95% CI, 0.36-0.83; P = 0.003) for endometrial cancer (this difference was not significant in the initial results), 0.19 (95% CI, 0.12-0.29) for uterine hyperplasia, and 0.75 (95% CI, 0.60-0.93) for thromboembolic events. There were no significant mortality differences. Long-term raloxifene retained 76% of the effectiveness of tamoxifen in preventing invasive disease and grew closer over time to tamoxifen in preventing noninvasive disease, with far less toxicity (e.g., highly significantly less endometrial cancer). These results have important public health implications and clarify that both raloxifene and tamoxifen are good preventive choices for postmenopausal women with elevated risk for breast cancer.
Vogel
Victor G
VG
NSABP, Pittsburgh, PA 15212, USA.
Costantino
Joseph P
JP
Wickerham
D Lawrence
DL
Cronin
Walter M
WM
Cecchini
Reena S
RS
Atkins
James N
JN
Bevers
Therese B
TB
Fehrenbacher
Louis
L
Pajon
Eduardo R
ER
Wade
James L
JL
Robidoux
André
A
Margolese
Richard G
RG
James
Joan
J
Runowicz
Carolyn D
CD
Ganz
Patricia A
PA
Reis
Steven E
SE
McCaskill-Stevens
Worta
W
Ford
Leslie G
LG
Jordan
V Craig
VC
Wolmark
Norman
N
D000230:Adenocarcinoma / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control*; D002386:Cataract / Q000139:chemically induced / Q000453:epidemiology; D004311:Double-Blind Method; D004363:Drug Utilization; D016889:Endometrial Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D004967:Estrogens; D005260:Female; D005500:Follow-Up Studies; D005598:Fractures, Spontaneous / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000453:epidemiology / Q000517:prevention & control; D009361:Neoplasm Invasiveness; D009376:Neoplasms, Hormone-Dependent / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control*; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000517:prevention & control; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D012306:Risk; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013629:Tamoxifen / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013923:Thromboembolism / Q000139:chemically induced / Q000453:epidemiology; D014599:Uterus / Q000473:pathology
D004967:Estrogens; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride
J Natl Cancer Inst. 1999 Sep 15;91(18):1541-8
10491430
JAMA. 2001 Nov 14;286(18):2251-6
11710890
JAMA. 2006 Jun 21;295(23):2727-41
16754727
Lancet. 2004 Sep 4-10;364(9437):858-68
15351193
N Engl J Med. 2006 Jul 13;355(2):125-37
16837676
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Lancet. 1999 Jun 12;353(9169):1993-2000
10376613
Lancet. 2002 Sep 14;360(9336):817-24
12243915
Endocrinology. 1983 Aug;113(2):463-8
6872937
Arterioscler Thromb Vasc Biol. 2001 Feb;21(2):255-61
11156862
J Natl Cancer Inst. 2006 Jan 18;98(2):110-5
16418513
J Natl Cancer Inst. 2007 Feb 21;99(4):283-90
17312305
J Natl Cancer Inst. 2007 Feb 21;99(4):272-82
17312304
Lancet. 2003 Jan 25;361(9354):296-300
12559863
J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61
15572757
Stat Med. 1992 Apr;11(6):813-29
1594819
Eur J Cancer. 1980 Feb;16(2):239-51
6768559
J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88
9747868
Lancet. 2005 May 14-20;365(9472):1687-717
15894097
J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62
16288118
Cancer Res. 1987 Aug 1;47(15):4020-4
3607747
Br J Haematol. 2003 Jan;120(1):109-16
12492585
J Clin Oncol. 2008 Jun 20;26(18):3073-82
18519949
JAMA. 1999 Jun 16;281(23):2189-97
10376571
Lancet. 1998 May 16;351(9114):1451-67
9605801
J Natl Cancer Inst. 2006 Jul 5;98(13):904-10
16818854
Oncology. 1988;45(5):344-5
3412740